McLaren Health Care Corporation · Detroit, MI
3 of 5
CMS star rating
115
Beds
2,351
Inpatient discharges a year
$401.6M
Net patient revenue a year
26
In-network payers
Karmanos Cancer Institute is a 115-bed proprietary hospital in Detroit, MI, affiliated with McLaren Health Care Corporation. Below you'll find publicly disclosed negotiated rates and facility details, including 26 in-network payers and 299 disclosed rate categories.
The 24 services Karmanos Cancer Institute most likely performs, ranked by likely volume and what it is paid. Each service names one insurer. * marks hidden insurer names; A, B and C rank the remaining rates from low to high and reset for each service.
Book a demo to see hidden insurer names, more payer rates, and hospital data, or start a free trial.
CT imaging
CPT 74177
$277 - $2,049
from 3 insurers · median $767
Common here, based on CMS Medicare volume
Gynecology
CPT 58571
$8,493 - $8,653
from 2 insurers · median $8,573
26 Medicare claims in Level 2 Laparoscopy and Related Services (CMS 2024)
Medicine & Surgery · Inpatient
MS-DRG 460
$43,828 - $63,952
from 2 insurers · median $53,890
Hospital reports neurosurgical services to CMS
Mammography
CPT 77067
$88 - $424
from 3 insurers · median $229
Common here, based on CMS Medicare volume
Nuclear imaging
CPT 78815
$1,135 - $3,807
from 3 insurers · median $3,216
Common here, based on CMS Medicare volume
Cardiology and vascular testing
CPT 93306
$320 - $1,096
from 2 insurers · median $708
Common here, based on CMS Medicare volume
Medicine & Surgery
CPT 47562
$6,141 - $6,511
from 2 insurers · median $6,326
21 Medicare claims in Level 1 Laparoscopy and Related Services (CMS 2024)
CT imaging
CPT 71275
$139 - $2,901
from 3 insurers · median $696
Common here, based on CMS Medicare volume
Medicine & Surgery
CPT 55866
$8,808 - $14,114
from 2 insurers · median $11,461
26 Medicare claims in Level 2 Laparoscopy and Related Services (CMS 2024)
Medicine & Surgery
CPT 66984
$3,791 - $3,899
from 2 insurers · median $3,845
Typical for a hospital with this service line
Medicine & Surgery · Inpatient
MS-DRG 473
$22,956 - $31,023
from 3 insurers · median $24,994
Hospital reports neurosurgical services to CMS
Digestive procedures
CPT 49650
$6,021 - $6,141
from 2 insurers · median $6,081
21 Medicare claims in Level 1 Laparoscopy and Related Services (CMS 2024)
Cardiology and vascular testing
CPT 93971
$335 - $869
from 3 insurers · median $799
Common here, based on CMS Medicare volume
MRI imaging
CPT 70553
$277 - $5,431
from 3 insurers · median $740
Common here, based on CMS Medicare volume
Digestive procedures
CPT 43239
$660 - $3,319
from 3 insurers · median $1,001
Common here, based on CMS Medicare volume
Urology
CPT 52000
$909 - $2,475
from 3 insurers · median $1,147
154 Medicare claims in Level 2 Urology and Related Services (CMS 2024)
CT imaging
CPT 70450
$83 - $225
from 2 insurers · median $154
Common here, based on CMS Medicare volume
CT imaging
CPT 74176
$189 - $1,837
from 3 insurers · median $354
Common here, based on CMS Medicare volume
Digestive procedures
CPT 45385
$1,034 - $3,319
from 3 insurers · median $1,069
Common here, based on CMS Medicare volume
X-ray and bone density
CPT 71046
$69 - $227
from 3 insurers · median $77
Common here, based on CMS Medicare volume
Digestive procedures
CPT 45380
$915 - $3,319
from 3 insurers · median $1,069
Common here, based on CMS Medicare volume
Gynecology
CPT 58558
$3,791 - $4,275
from 2 insurers · median $4,033
Typical for a hospital with this service line
Ultrasound
CPT 76830
$83 - $1,095
from 3 insurers · median $309
Common here, based on CMS Medicare volume
Gynecology
CPT 58661
$5,693 - $6,141
from 2 insurers · median $5,917
Typical for a hospital with this service line
Median rate as a percent of Medicare across the outpatient services above, and how many services sit above or below the same insurer's median at nearby hospitals. * marks hidden insurer names. These table labels track the same insurers across services; the labels on each service card reset.
| Insurer | Services | Median % of Medicare | Above nearby | Below nearby |
|---|---|---|---|---|
| Insurer A* | 15 | 498% | 4 | 6 |
| Insurer B* | 24 | 138% | 4 | 18 |
| Insurer C* | 23 | 99% | 6 | 16 |
How we chose these services: 5 appear in this hospital's own Medicare claims, 14 are common here based on CMS Medicare volume, and 5 are typical for the service lines it reports to CMS. Rates come from insurer and hospital price transparency files as of October 2026. Rates under a quarter of Medicare or over 20 times Medicare are left out as likely physician-fee rows or file errors. Book a demo to see all 300 CMS shoppable services for Karmanos Cancer Institute, or start a free trial.
Acceptance varies by plan and service. Confirm coverage with your insurer or the hospital's billing department.
Quality
3 of 5 stars
Doctors and services
Accredited by The Joint Commission
Finances
$401.6M net patient revenue
Ownership and leadership
Owned by Barbara Ann Karmanos Cancer Institute
The employer identification numbers (EINs) health plans and networks list for Karmanos Cancer Institute in the in-network rate files they publish, with the organization NPIs billed under each.
| Tax ID (EIN) | Plans and networks listing it | Organization NPIs |
|---|---|---|
| 20-1649466Barbara Ann Karmanos Cancer Hospital | 46Aetna, Cigna, United Healthcare (incl Optum, Rocky Mountain, Health Plan of Nevada, Sierra Health), Allied Benefit Systems, Ambetter and 41 more | 1316900277 Barbara Ann Karmanos Cancer Hospital1043755788 Barbara Ann Karmanos Cancer Center1871913228 Ascension Medical Group Michiganand 4 more |
Source: PayerPrice analysis of insurers' Transparency in Coverage in-network files. An EIN can cover several hospitals and clinics in a health system, and insurers sometimes list other organizations' NPIs under it.
4100 John 'r' Street, Detroit, MI 48201
(800) 576-6266
How Karmanos Cancer Institute compares with other US facilities on the measures CMS publishes, mostly from Medicare patients.
Overall star rating
3 of 5
Lower than 42% of US hospitals
Combines death rates, safety, readmissions, patient experience and timely care
Death rates
No different on 2 measures
0 better, 2 no different, 0 worse than the US rate
Deaths within 30 days, such as after a heart attack, pneumonia or stroke
Safety
No different on 5 measures
0 better, 5 no different, 0 worse than the US rate
Infections, surgical complications and other harm in the hospital
Readmissions
No different on 6 measures
0 better, 6 no different, 0 worse than the US rate
Patients back in the hospital or ER soon after leaving
Patient survey rating
4 of 5
Higher than 60% of US hospitals
From the HCAHPS survey of recent inpatients
Would definitely recommend
78%
Higher than 72% of US hospitals
US median: 71%
Surveyed patients who would definitely recommend the hospital
Hospital-acquired condition penalty
Not penalized
Not among the worst-performing 25%
Medicare cuts payments 1% for the worst-performing 25% of hospitals on infections and injuries acquired in the hospital
Serious complications (PSI 90)
1.01
Higher than 66% of US hospitals
US median: 0.96
Risk-adjusted composite of complications such as bedsores, falls with hip fracture and blood clots after surgery; lower is better
Sepsis care
33%
Lower than 96% of US hospitals
US median: 65%
Patients with severe sepsis or septic shock who got every step of the recommended early treatment; higher is better
| Measure | Result | Period |
|---|---|---|
| Overall star ratingCMS: Overall hospital quality star rating | 3 of 5 | |
| Death rates | No different on 2 measures | |
| Safety | No different on 5 measures | |
| Readmissions | No different on 6 measures | |
| Patient survey ratingCMS: Summary star rating | 4 of 5 | 2024-10-01 to 2025-09-30 |
| Would definitely recommendCMS: "YES", patients would definitely recommend the hospital | 78% | 2024-10-01 to 2025-09-30 |
| Hospital-acquired condition penaltyCMS: HAC Reduction Program payment reduction | Not penalized | 2026 |
| Serious complications (PSI 90)CMS: Patient safety and adverse events composite (PSI 90) | 1.01 | 2022-07-01 to 2024-06-30 |
| Sepsis careCMS: Appropriate care for severe sepsis and septic shock | 33% | 2024-10-01 to 2025-09-30 |
Source: CMS Provider Data Catalog, released 2026-08-13. US comparisons rank this facility among every facility CMS reports for each measure. See Medicare Care Compare.
How Medicare adjusts Karmanos Cancer Institute's inpatient payments for its readmissions, quality and cost results.
No penalty
Readmissions penalty
Hospital Readmissions Reduction Program adjustment for excess readmissions, as estimated in the FY 2027 IPPS final rule.
0.00% on Medicare payments
Value-based purchasing
Hospital Value-Based Purchasing bonus or reduction for quality and cost, as estimated in the FY 2027 IPPS final rule.
Source: CMS IPPS final rule Impact File (FY 2027).
Each result CMS publishes for Karmanos Cancer Institute, beside the US median and the average of MI hospitals. The rank says what share of US hospitals the result is better or worse than; counts and confidence limits are not ranked.
Risk-adjusted 30-day death rates and surgical complications; lower is better.
| Measure | Karmanos Cancer Institute | US median | MI average | CMS comparison | US rank |
|---|---|---|---|---|---|
| Rate of complications for hip/knee replacement patients2023-04-01 to 2025-03-31 | Not Available | 4.186 | |||
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality Rate2024-07-01 to 2025-06-30 · 310 cases | 3.4 | 3.9 | 3.903 | Better than 79% of US hospitals | |
| Death rate for heart attack patients2022-07-01 to 2025-06-30 | Not Available | 12 | |||
| Death rate for CABG surgery patients2022-07-01 to 2025-06-30 | Not Available | 2.376 | |||
| Death rate for COPD patients2022-07-01 to 2025-06-30 | Not Available | 8.576 | |||
| Death rate for heart failure patients2022-07-01 to 2025-06-30 | Not Available | 11.26 | |||
| Death rate for pneumonia patients2022-07-01 to 2025-06-30 · 41 cases | 16.3 | 15.2 | 15.18 | Worse than 66% of US hospitals | |
| Death rate for stroke patients2023-07-01 to 2025-06-30 | Not Available | 11.95 | |||
| Pressure ulcer rate2022-07-01 to 2024-06-30 · 791 cases | 0.4 | 0.51 | 0.6149 | No Different Than the National Rate | Better than 67% of US hospitals |
| Death rate among surgical inpatients with serious treatable complications2022-07-01 to 2024-06-30 | Not Available | 178 | Number of Cases Too Small | ||
| Iatrogenic pneumothorax rate2022-07-01 to 2024-06-30 · 803 cases | 0.2 | 0.2 | 0.2198 | No Different Than the National Rate | Better than 46% of US hospitals |
| In-hospital fall-associated fracture rate2022-07-01 to 2024-06-30 · 953 cases | 0.26 | 0.27 | 0.2762 | No Different Than the National Rate | Better than 54% of US hospitals |
| Postoperative hemorrhage or hematoma rate2022-07-01 to 2024-06-30 · 206 cases | 3.53 | 2.29 | 2.378 | No Different Than the National Rate | Worse than 99% of US hospitals |
| Postoperative acute kidney injury requiring dialysis rate2022-07-01 to 2024-06-30 · 143 cases | 1.59 | 1.63 | 1.689 | No Different Than the National Rate | Better than 65% of US hospitals |
| Postoperative respiratory failure rate2022-07-01 to 2024-06-30 · 72 cases | 7.58 | 8.88 | 9.51 | No Different Than the National Rate | Better than 78% of US hospitals |
| Perioperative pulmonary embolism or deep vein thrombosis rate2022-07-01 to 2024-06-30 · 232 cases | 4.36 | 3.4 | 3.553 | No Different Than the National Rate | Worse than 90% of US hospitals |
| Postoperative sepsis rate2022-07-01 to 2024-06-30 · 146 cases | 6.5 | 5.105 | 5.252 | No Different Than the National Rate | Worse than 87% of US hospitals |
| Postoperative wound dehiscence rate2022-07-01 to 2024-06-30 · 76 cases | 2.04 | 1.72 | 1.76 | No Different Than the National Rate | Worse than 89% of US hospitals |
| Abdominopelvic accidental puncture or laceration rate2022-07-01 to 2024-06-30 · 227 cases | 2.02 | 1.02 | 1.117 | No Different Than the National Rate | Worse than 99% of US hospitals |
Unplanned returns to a hospital after a stay or an outpatient procedure; lower is better.
| Measure | Karmanos Cancer Institute | US median | MI average | CMS comparison | US rank |
|---|---|---|---|---|---|
| Hospital return days for heart attack patients2022-07-01 to 2025-06-30 | Not Available | 9.875 | |||
| Hospital return days for heart failure patients2022-07-01 to 2025-06-30 | Not Available | 2.533 | |||
| Hospital return days for pneumonia patients2022-07-01 to 2025-06-30 · 48 cases | -23.8 | 3.85 | 5.307 | Better than 84% of US hospitals | |
| Hybrid Hospital-Wide All-Cause Readmission Measure (HWR)2024-07-01 to 2025-06-30 | Not Available | ||||
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)2022-01-01 to 2024-12-31 · 64 cases | 13 | 12.9 | 12.94 | No Different Than the National Rate | Worse than 50% of US hospitals |
| Rate of inpatient admissions for patients receiving outpatient chemotherapy2024-01-01 to 2024-12-31 · 448 cases | 9.2 | 10.7 | 10.6 | No Different Than the National Rate | Better than 91% of US hospitals |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy2024-01-01 to 2024-12-31 · 448 cases | 5.3 | 5.3 | 5.333 | No Different Than the National Rate | Better than 48% of US hospitals |
| Ratio of unplanned hospital visits after hospital outpatient surgery2024-01-01 to 2024-12-31 · 91 cases | 0.9 | 1 | 0.9865 | No Different than expected | Better than 68% of US hospitals |
| Acute Myocardial Infarction (AMI) 30-Day Readmission Rate2023-07-01 to 2025-06-30 | Not Available | 14.28 | |||
| Rate of readmission for CABG2023-07-01 to 2025-06-30 | Not Available | 10.41 | |||
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patients2023-07-01 to 2025-06-30 | Not Available | 19.73 | |||
| Heart failure (HF) 30-Day Readmission Rate2023-07-01 to 2025-06-30 | Not Available | 21.19 | |||
| Rate of readmission after hip/knee replacement2023-07-01 to 2025-06-30 | Not Available | 5.984 | |||
| Pneumonia (PN) 30-Day Readmission Rate2023-07-01 to 2025-06-30 · 79 cases | 16.8 | 17.2 | 17.08 | Better than 68% of US hospitals |
Standardized infection ratios (1 is the US baseline) and the counts behind them; lower is better.
| Measure | Karmanos Cancer Institute | US median | MI average | CMS comparison | US rank |
|---|---|---|---|---|---|
| Central Line Associated Bloodstream Infection (ICU + select Wards): Lower Confidence Limit2024-10-01 to 2025-09-30 | 0.039 | 0.172 | 0.2592 | No Different than National Benchmark | |
| Central Line Associated Bloodstream Infection (ICU + select Wards): Upper Confidence Limit2024-10-01 to 2025-09-30 | 3.838 | 1.504 | 1.909 | No Different than National Benchmark | |
| Central Line Associated Bloodstream Infection: Number of Device Days2024-10-01 to 2025-09-30 | 1,474 | 1,370 | 4,065 | No Different than National Benchmark | |
| Central Line Associated Bloodstream Infection (ICU + select Wards): Predicted Cases2024-10-01 to 2025-09-30 | 1.285 | 0.9835 | 4.274 | No Different than National Benchmark | |
| Central Line Associated Bloodstream Infection (ICU + select Wards): Observed Cases2024-10-01 to 2025-09-30 | 1 | 0 | 2.649 | No Different than National Benchmark | |
| Central Line Associated Bloodstream Infection (ICU + select Wards)2024-10-01 to 2025-09-30 | 0.778 | 0.484 | 0.6721 | No Different than National Benchmark | Worse than 73% of US hospitals |
| Catheter Associated Urinary Tract Infections (ICU + select Wards): Lower Confidence Limit2024-10-01 to 2025-09-30 | Not Available | 0.1561 | No Different than National Benchmark | ||
| Catheter Associated Urinary Tract Infections (ICU + select Wards): Upper Confidence Limit2024-10-01 to 2025-09-30 | 1.862 | 1.392 | 1.389 | No Different than National Benchmark | |
| Catheter Associated Urinary Tract Infections (ICU + select Wards): Number of Urinary Catheter Days2024-10-01 to 2025-09-30 | 1,757 | 1,799 | 4,188 | No Different than National Benchmark | |
| Catheter Associated Urinary Tract Infections (ICU + select Wards): Predicted Cases2024-10-01 to 2025-09-30 | 1.609 | 1.377 | 5.413 | No Different than National Benchmark | |
| Catheter Associated Urinary Tract Infections (ICU + select Wards): Observed Cases2024-10-01 to 2025-09-30 | 0 | 0 | 2.168 | No Different than National Benchmark | |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)2024-10-01 to 2025-09-30 | 0 | 0.399 | 0.3966 | No Different than National Benchmark | The best result, shared by 24% of US hospitals |
| SSI - Colon Surgery: Lower Confidence Limit2024-10-01 to 2025-09-30 | Not Available | 0.4382 | |||
| SSI - Colon Surgery: Upper Confidence Limit2024-10-01 to 2025-09-30 | Not Available | 2.741 | |||
| SSI - Colon Surgery: Number of Procedures2024-10-01 to 2025-09-30 | Not Available | 118 | |||
| SSI - Colon Surgery: Predicted Cases2024-10-01 to 2025-09-30 | Not Available | 3.112 | |||
| SSI - Colon Surgery: Observed Cases2024-10-01 to 2025-09-30 | Not Available | 3.074 | |||
| SSI - Colon Surgery2024-10-01 to 2025-09-30 | Not Available | 1.049 | |||
| SSI - Abdominal Hysterectomy: Lower Confidence Limit2024-10-01 to 2025-09-30 | Not Available | 0.6144 | |||
| SSI - Abdominal Hysterectomy: Upper Confidence Limit2024-10-01 to 2025-09-30 | Not Available | 4.322 | |||
| SSI - Abdominal Hysterectomy: Number of Procedures2024-10-01 to 2025-09-30 | Not Available | 75.28 | |||
| SSI - Abdominal Hysterectomy: Predicted Cases2024-10-01 to 2025-09-30 | Not Available | 0.6545 | |||
| SSI - Abdominal Hysterectomy: Observed Cases2024-10-01 to 2025-09-30 | Not Available | 0.9634 | |||
| SSI - Abdominal Hysterectomy2024-10-01 to 2025-09-30 | Not Available | 1.462 | |||
| MRSA Bacteremia: Lower Confidence Limit2024-10-01 to 2025-09-30 | 0.424 | 0.193 | 0.2675 | No Different than National Benchmark | |
| MRSA Bacteremia: Upper Confidence Limit2024-10-01 to 2025-09-30 | 3.219 | 1.855 | 2.176 | No Different than National Benchmark | |
| MRSA Bacteremia: Patient Days2024-10-01 to 2025-09-30 | 22,977 | 14,451 | 42,903 | No Different than National Benchmark | |
| MRSA Bacteremia: Predicted Cases2024-10-01 to 2025-09-30 | 2.997 | 0.567 | 2.796 | No Different than National Benchmark | |
| MRSA Bacteremia: Observed Cases2024-10-01 to 2025-09-30 | 4 | 0 | 1.826 | No Different than National Benchmark | |
| MRSA Bacteremia2024-10-01 to 2025-09-30 | 1.335 | 0.597 | 0.7532 | No Different than National Benchmark | Worse than 90% of US hospitals |
| Clostridium Difficile (C.Diff): Lower Confidence Limit2024-10-01 to 2025-09-30 | 0.651 | 0.127 | 0.1572 | No Different than National Benchmark | |
| Clostridium Difficile (C.Diff): Upper Confidence Limit2024-10-01 to 2025-09-30 | 1.409 | 0.747 | 1.134 | No Different than National Benchmark | |
| Clostridium Difficile (C.Diff): Patient Days2024-10-01 to 2025-09-30 | 22,977 | 13,646 | 40,305 | No Different than National Benchmark | |
| Clostridium Difficile (C.Diff): Predicted Cases2024-10-01 to 2025-09-30 | 26.65 | 5.683 | 21.05 | No Different than National Benchmark | |
| Clostridium Difficile (C.Diff): Observed Cases2024-10-01 to 2025-09-30 | 26 | 2 | 6.934 | No Different than National Benchmark | |
| Clostridium Difficile (C.Diff)2024-10-01 to 2025-09-30 | 0.976 | 0.279 | 0.3227 | No Different than National Benchmark | Worse than 94% of US hospitals |
How recent inpatients answered each survey question, with CMS's star rating per topic.
| Measure | Karmanos Cancer Institute | US median | MI average | CMS comparison | US rank |
|---|---|---|---|---|---|
| Room was "always" clean2024-10-01 to 2025-09-30 · 397 cases | 68 | 73 | 69.3 | Worse than 71% of US hospitals | |
| Room was "sometimes" or "never" clean2024-10-01 to 2025-09-30 · 397 cases | 8 | 8 | 10.85 | Better than 47% of US hospitals | |
| Room was "usually" clean2024-10-01 to 2025-09-30 · 397 cases | 24 | 18 | 19.85 | ||
| Cleanliness - linear mean score2024-10-01 to 2025-09-30 · 397 cases | 86 | 87 | 84.11 | Worse than 53% of US hospitals | |
| Cleanliness - star rating2024-10-01 to 2025-09-30 · 397 cases | 3 | 4 | 2.86 | Worse than 53% of US hospitals | |
| Nurses "always" communicated well2024-10-01 to 2025-09-30 · 397 cases | 85 | 80 | 79.59 | Better than 79% of US hospitals | |
| Nurse communication - linear mean score2024-10-01 to 2025-09-30 · 397 cases | 94 | 91 | 91.42 | Better than 82% of US hospitals | |
| Nurses "sometimes" or "never" communicated well2024-10-01 to 2025-09-30 · 397 cases | 2 | 4 | 4.111 | Better than 76% of US hospitals | |
| Nurse communication - star rating2024-10-01 to 2025-09-30 · 397 cases | 5 | 3 | 3.5 | The top rating, shared by 18% of US hospitals | |
| Nurses "usually" communicated well2024-10-01 to 2025-09-30 · 397 cases | 13 | 16 | 16.3 | ||
| Doctors "always" communicated well2024-10-01 to 2025-09-30 · 397 cases | 80 | 79 | 78.2 | Better than 53% of US hospitals | |
| Doctor communication - linear mean score2024-10-01 to 2025-09-30 · 397 cases | 92 | 91 | 90.27 | Better than 63% of US hospitals | |
| Doctors "sometimes" or "never" communicated well2024-10-01 to 2025-09-30 · 397 cases | 4 | 5 | 5.521 | Better than 62% of US hospitals | |
| Doctor communication - star rating2024-10-01 to 2025-09-30 · 397 cases | 4 | 3 | 3.07 | Better than 63% of US hospitals | |
| Doctors "usually" communicated well2024-10-01 to 2025-09-30 · 397 cases | 16 | 16 | 16.28 | ||
| Staff "always" explained2024-10-01 to 2025-09-30 · 397 cases | 69 | 61 | 61.03 | Better than 81% of US hospitals | |
| Communication about medicines - linear mean score2024-10-01 to 2025-09-30 · 397 cases | 83 | 77 | 76.51 | Better than 88% of US hospitals | |
| Staff "sometimes" or "never" explained2024-10-01 to 2025-09-30 · 397 cases | 13 | 19 | 19.58 | Better than 83% of US hospitals | |
| Communication about medicines - star rating2024-10-01 to 2025-09-30 · 397 cases | 4 | 3 | 2.63 | Better than 79% of US hospitals | |
| Staff "usually" explained2024-10-01 to 2025-09-30 · 397 cases | 18 | 19 | 19.38 | ||
| Discharge information - linear mean score2024-10-01 to 2025-09-30 · 397 cases | 90 | 86 | 85.82 | Better than 86% of US hospitals | |
| No, staff "did not" give patients this information2024-10-01 to 2025-09-30 · 397 cases | 10 | 13 | 13.17 | Better than 78% of US hospitals | |
| Discharge information - star rating2024-10-01 to 2025-09-30 · 397 cases | 4 | 3 | 3.35 | Better than 55% of US hospitals | |
| Yes, staff "did" give patients this information2024-10-01 to 2025-09-30 · 397 cases | 90 | 87 | 86.83 | Better than 78% of US hospitals | |
| No, staff "did not" give patients information about help after discharge2024-10-01 to 2025-09-30 · 397 cases | 9 | 14 | 14.7 | Better than 88% of US hospitals | |
| Yes, staff "did" give patients information about help after discharge2024-10-01 to 2025-09-30 · 397 cases | 91 | 86 | 85.3 | Better than 88% of US hospitals | |
| Doctors "always" explained things so they could understand2024-10-01 to 2025-09-30 · 397 cases | 74 | 74 | 72.65 | Better than 48% of US hospitals | |
| Doctors "sometimes" or "never" explained things so they could understand2024-10-01 to 2025-09-30 · 397 cases | 5 | 7 | 7.064 | Better than 68% of US hospitals | |
| Doctors "usually" explained things so they could understand2024-10-01 to 2025-09-30 · 397 cases | 21 | 19 | 20.28 | ||
| Doctors "always" listened carefully2024-10-01 to 2025-09-30 · 397 cases | 77 | 77 | 75.91 | Worse than 49% of US hospitals | |
| Doctors "sometimes" or "never" listened carefully2024-10-01 to 2025-09-30 · 397 cases | 4 | 6 | 6.191 | Better than 70% of US hospitals | |
| Doctors "usually" listened carefully2024-10-01 to 2025-09-30 · 397 cases | 19 | 17 | 17.9 | ||
| Doctors "always" treated them with courtesy and respect2024-10-01 to 2025-09-30 · 397 cases | 88 | 85 | 84.26 | Better than 70% of US hospitals | |
| Doctors "sometimes" or "never" treated them with courtesy and respect2024-10-01 to 2025-09-30 · 397 cases | 2 | 3 | 3.827 | Better than 75% of US hospitals | |
| Doctors "usually" treated them with courtesy and respect2024-10-01 to 2025-09-30 · 397 cases | 10 | 11 | 11.91 | ||
| Patients who gave a rating of "6" or lower (low)2024-10-01 to 2025-09-30 · 397 cases | 5 | 8 | 9.248 | Better than 73% of US hospitals | |
| Patients who gave a rating of "7" or "8" (medium)2024-10-01 to 2025-09-30 · 397 cases | 17 | 20 | 21.47 | ||
| Patients who gave a rating of "9" or "10" (high)2024-10-01 to 2025-09-30 · 397 cases | 78 | 72 | 69.28 | Better than 74% of US hospitals | |
| Overall hospital rating - linear mean score2024-10-01 to 2025-09-30 · 397 cases | 91 | 88 | 87.04 | Better than 77% of US hospitals | |
| Overall hospital rating - star rating2024-10-01 to 2025-09-30 · 397 cases | 4 | 3 | 3.12 | Better than 55% of US hospitals | |
| Staff "always" explained new medications2024-10-01 to 2025-09-30 · 397 cases | 83 | 74 | 74.28 | Better than 90% of US hospitals | |
| Staff "sometimes" or "never" explained new medications2024-10-01 to 2025-09-30 · 397 cases | 6 | 9 | 9.173 | Better than 79% of US hospitals | |
| Staff "usually" explained new medications2024-10-01 to 2025-09-30 · 397 cases | 11 | 16 | 16.55 | ||
| Nurses "always" explained things so they could understand2024-10-01 to 2025-09-30 · 397 cases | 80 | 75 | 74.9 | Better than 79% of US hospitals | |
| Nurses "sometimes" or "never" explained things so they could understand2024-10-01 to 2025-09-30 · 397 cases | 3 | 5 | 5.573 | Better than 81% of US hospitals | |
| Nurses "usually" explained things so they could understand2024-10-01 to 2025-09-30 · 397 cases | 17 | 20 | 19.53 | ||
| Nurses "always" listened carefully2024-10-01 to 2025-09-30 · 397 cases | 83 | 77 | 76.58 | Better than 82% of US hospitals | |
| Nurses "sometimes" or "never" listened carefully2024-10-01 to 2025-09-30 · 397 cases | 3 | 4 | 4.364 | Better than 64% of US hospitals | |
| Nurses "usually" listened carefully2024-10-01 to 2025-09-30 · 397 cases | 14 | 19 | 19.05 | ||
| Nurses "always" treated them with courtesy and respect2024-10-01 to 2025-09-30 · 397 cases | 91 | 86 | 85.7 | Better than 83% of US hospitals | |
| Nurses "sometimes" or "never" treated them with courtesy and respect2024-10-01 to 2025-09-30 · 397 cases | 1 | 3 | 2.773 | Better than 77% of US hospitals | |
| Nurses "usually" treated them with courtesy and respect2024-10-01 to 2025-09-30 · 397 cases | 8 | 11 | 11.53 | ||
| "Always" quiet at night2024-10-01 to 2025-09-30 · 397 cases | 64 | 59 | 56.73 | Better than 65% of US hospitals | |
| "Sometimes" or "never" quiet at night2024-10-01 to 2025-09-30 · 397 cases | 6 | 9 | 11.16 | Better than 70% of US hospitals | |
| "Usually" quiet at night2024-10-01 to 2025-09-30 · 397 cases | 30 | 31 | 32.11 | ||
| Quietness - linear mean score2024-10-01 to 2025-09-30 · 397 cases | 86 | 82 | 80.12 | Better than 79% of US hospitals | |
| Quietness - star rating2024-10-01 to 2025-09-30 · 397 cases | 4 | 3 | 3.12 | Better than 56% of US hospitals | |
| "NO", patients would not recommend the hospital (they probably would not or definitely would not recommend it)2024-10-01 to 2025-09-30 · 397 cases | 3 | 5 | 6.291 | Better than 70% of US hospitals | |
| "YES", patients would definitely recommend the hospital2024-10-01 to 2025-09-30 · 397 cases | 78 | 71 | 68.51 | Better than 72% of US hospitals | |
| Recommend hospital - linear mean score2024-10-01 to 2025-09-30 · 397 cases | 91 | 87 | 85.75 | Better than 76% of US hospitals | |
| "YES", patients would probably recommend the hospital2024-10-01 to 2025-09-30 · 397 cases | 19 | 23 | 25.2 | ||
| Recommend hospital - star rating2024-10-01 to 2025-09-30 · 397 cases | 5 | 4 | 3.39 | The top rating, shared by 24% of US hospitals | |
| Staff "always" explained possible side effects2024-10-01 to 2025-09-30 · 397 cases | 54 | 47 | 46.3 | Better than 78% of US hospitals | |
| Staff "sometimes" or "never" explained possible side effects2024-10-01 to 2025-09-30 · 397 cases | 20 | 30 | 30.8 | Better than 89% of US hospitals | |
| Staff "usually" explained possible side effects2024-10-01 to 2025-09-30 · 397 cases | 26 | 22 | 22.9 | ||
| Summary star rating2024-10-01 to 2025-09-30 · 397 cases | 4 | 3 | 3.21 | Better than 60% of US hospitals | |
| No, staff "did not" give patients information about possible symptoms2024-10-01 to 2025-09-30 · 397 cases | 10 | 12 | 12.2 | Better than 70% of US hospitals | |
| Yes, staff "did" give patients information about possible symptoms2024-10-01 to 2025-09-30 · 397 cases | 90 | 88 | 87.8 | Better than 70% of US hospitals |
How often the hospital gave recommended care, and how fast.
| Measure | Karmanos Cancer Institute | US median | MI average | CMS comparison | US rank |
|---|---|---|---|---|---|
| Emergency department volume2024-01-01 to 2024-12-31 | Not Available | ||||
| Global Malnutrition Composite Score2024-01-01 to 2024-12-31 | Not Available | ||||
| Global Malnutrition Composite Score: Malnutrition Diagnosis Documented2024-01-01 to 2024-12-31 | Not Available | ||||
| Global Malnutrition Composite Score: Malnutrition Risk Screening2024-01-01 to 2024-12-31 | Not Available | ||||
| Global Malnutrition Composite Score: Nutrition Assessment2024-01-01 to 2024-12-31 | Not Available | ||||
| Global Malnutrition Composite Score: Nutritional Care Plan2024-01-01 to 2024-12-31 | Not Available | ||||
| Hospital Harm - Severe Hyperglycemia2024-01-01 to 2024-12-31 | Not Available | 8.08 | |||
| Hospital Harm - Severe Hypoglycemia2024-01-01 to 2024-12-31 | Not Available | 0.9722 | |||
| Hospital Harm - Opioid Related Adverse Events2024-01-01 to 2024-12-31 | Not Available | 0.4118 | |||
| Healthcare workers given influenza vaccination2024-10-01 to 2025-03-31 · 1,775 cases | 75 | 79 | 74.71 | Worse than 57% of US hospitals | |
| Average (median) time all patients spent in the emergency department before leaving from the visit, including psychiatric/mental health patients and patients who were transferred to another facility. A lower number of minutes is better2024-10-01 to 2025-09-30 | Not Available | 167 | |||
| Average (median) time patients spent in the emergency department before leaving from the visit, excluding patients transferred to another facility or psychiatric care/mental health patients. A lower number of minutes is better2024-10-01 to 2025-09-30 | Not Available | 161 | |||
| Average (median) time psychiatric/mental health patients spent in the emergency department before leaving from the visit. A lower number of minutes is better2024-10-01 to 2025-09-30 | Not Available | 300 | |||
| Average (median) time patients spent in the emergency department before being transferred to another facility. A lower number of minutes is better2024-10-01 to 2025-09-30 | Not Available | 338 | |||
| Left before being seen2024-01-01 to 2024-12-31 | Not Available | 1.933 | |||
| Head CT results2024-10-01 to 2025-09-30 | Not Available | 73.42 | |||
| Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients2024-01-01 to 2024-12-31 · 21 cases | 71 | 97 | 93.2 | Worse than 94% of US hospitals | |
| Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery2024-01-01 to 2024-12-31 | Not Available | ||||
| ST-Segment Elevation Myocardial Infarction (STEMI)2024-01-01 to 2024-12-31 | Not Available | 39.25 | |||
| Safe Use of Opioids - Concurrent Prescribing2024-01-01 to 2024-12-31 · 82 cases | 13 | 15 | 15.67 | Better than 60% of US hospitals | |
| Appropriate care for severe sepsis and septic shock2024-10-01 to 2025-09-30 · 18 cases | 33 | 65 | 59.69 | Worse than 96% of US hospitals | |
| Septic Shock 3-Hour Bundle2024-10-01 to 2025-09-30 | Not Available | 69.54 | |||
| Septic Shock 6-Hour Bundle2024-10-01 to 2025-09-30 | Not Available | 83.94 | |||
| Severe Sepsis 3-Hour Bundle2024-10-01 to 2025-09-30 · 18 cases | 56 | 82 | 77.12 | Worse than 97% of US hospitals | |
| Severe Sepsis 6-Hour Bundle2024-10-01 to 2025-09-30 | Not Available | 90.36 | |||
| Discharged on Antithrombotic Therapy2024-01-01 to 2024-12-31 | Not Available | 94.44 | |||
| Anticoagulation Therapy for Atrial Fibrillation/Flutter2024-01-01 to 2024-12-31 | Not Available | 69.44 | |||
| Antithrombotic Therapy by End of Hospital Day 22024-01-01 to 2024-12-31 | Not Available | 91.64 | |||
| Venous Thromboembolism Prophylaxis2024-01-01 to 2024-12-31 | Not Available | 82.06 | |||
| Intensive Care Unit Venous Thromboembolism Prophylaxis2024-01-01 to 2024-12-31 · 437 cases | 95 | 97 | 91 | Worse than 62% of US hospitals |
How often scans were ordered when they may not be needed; lower is better.
| Measure | Karmanos Cancer Institute | US median | MI average | CMS comparison | US rank |
|---|---|---|---|---|---|
| Abdomen CT Use of Contrast Material2024-07-01 to 2025-06-30 | 11.3 | 5 | 6.103 | Worse than 91% of US hospitals | |
| Breast Cancer Screening Recall Rates2024-07-01 to 2025-06-30 | 18.7 | 6.6 | 7.033 | Worse than 95% of US hospitals |
Medicare spending around an inpatient stay compared with the US (1 is the US median).
| Measure | Karmanos Cancer Institute | US median | MI average | CMS comparison | US rank |
|---|---|---|---|---|---|
| Medicare hospital spending per patient (Medicare Spending per Beneficiary)2024-01-01 to 2024-12-31 | 1.07 | 0.99 | 0.9406 | Worse than 85% of US hospitals |
Excess readmission ratios by condition; above 1 means more readmissions than expected.
| Measure | Karmanos Cancer Institute | US median | MI average | CMS comparison | US rank |
|---|---|---|---|---|---|
| READM-30-AMI-HRRP2021-07-01 to 2024-06-30 | N/A | 0.995 | |||
| READM-30-CABG-HRRP2021-07-01 to 2024-06-30 | N/A | 0.9907 | |||
| READM-30-COPD-HRRP2021-07-01 to 2024-06-30 | N/A | 0.9989 | |||
| READM-30-HF-HRRP2021-07-01 to 2024-06-30 | N/A | 1.002 | |||
| READM-30-HIP-KNEE-HRRP2021-07-01 to 2024-06-30 | N/A | 1.061 | |||
| READM-30-PN-HRRP2021-07-01 to 2024-06-30 | 0.9839 | 0.9955 | 0.9984 | Better than 58% of US hospitals |
| By fiscal year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|
| READM-30-AMI-HRRP | N/A | N/A | N/A | N/A | N/A | N/A |
| READM-30-CABG-HRRP | N/A | N/A | N/A | N/A | N/A | N/A |
| READM-30-COPD-HRRP | 0.9957 | 0.9865 | 0.9758 | N/A | N/A | N/A |
| READM-30-HF-HRRP | N/A | N/A | N/A | N/A | N/A | N/A |
| READM-30-HIP-KNEE-HRRP | N/A | N/A | N/A | N/A | N/A | N/A |
| READM-30-PN-HRRP | 0.9809 | 1.013 | 1.032 | 1.011 | 0.9758 | 0.9839 |
Infection ratios, the PSI 90 composite and the total score Medicare ranks hospitals on; lower is better.
| Measure | Karmanos Cancer Institute | US median | MI average | CMS comparison | US rank |
|---|---|---|---|---|---|
| CAUTI standardized infection ratio2023-01-01 to 2024-12-31 | 0.415 | 0.489 | 0.5894 | Better than 58% of US hospitals | |
| CDI standardized infection ratio2023-01-01 to 2024-12-31 | 0.765 | 0.346 | 0.3948 | Worse than 90% of US hospitals | |
| CLABSI standardized infection ratio2023-01-01 to 2024-12-31 | 0 | 0.559 | 0.7747 | The best result, shared by 14% of US hospitals | |
| HAC Reduction Program payment reductionFY 2026 | No | ||||
| MRSA standardized infection ratio2023-01-01 to 2024-12-31 | 1.439 | 0.6405 | 0.8034 | Worse than 90% of US hospitals | |
| Patient safety and adverse events composite (PSI 90)2022-07-01 to 2024-06-30 | 1.006 | 0.9628 | 1.007 | Worse than 66% of US hospitals | |
| SSI standardized infection ratio2023-01-01 to 2024-12-31 | N/A | 1.234 | |||
| Total HAC scoreFY 2026 | 0.2902 | -0.0453 | 0.1353 | Worse than 70% of US hospitals |
| By fiscal year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|
| HAC Reduction Program payment reduction | Yes | Yes | N/A | No | No | No |
| Total HAC score | 0.656 | 0.7554 | 0 | 0.2372 | 0.2544 | 0.2902 |
Source: CMS Care Compare hospital files, latest release 2026-09-30, with program results for earlier fiscal years from CMS's archived snapshots. US medians and ranks count every hospital CMS reports; state averages are plain means of the state's reporting hospitals, not CMS's patient-weighted state rates.
The Joint Commission (since 2020)
Accreditation
Major
Medical school affiliation
Private (for profit)
Ownership type
123
Medicare-certified beds
102
Registered nurses (full-time equivalent)
2005
In Medicare since
Source: CMS Provider of Services file, as reported by the hospital and state surveyors.
What Karmanos Cancer Institute reported to Medicare in its latest cost report, covering Oct 1, 2024 to Sep 30, 2025.
2,351
Inpatient discharges
Medicare 17%, Medicaid 2%
20,853
Inpatient days
56% of available bed days used
976
Employees (full-time equivalent)
58
Interns and residents (full-time equivalent)
Source: CMS cost report (HCRIS) (report 831495). Figures cover the reporting period, which is not always 12 months, and are self-reported.
Inpatient days and discharges Karmanos Cancer Institute reported by payer. Medicare and Medicaid include their managed care plans, shown separately below.
| Medicare | Medicaid | Other | Total | |
|---|---|---|---|---|
| Inpatient days | 3,641 | 257 | 16,955 | 20,853 |
| Discharges | 402 | 46 | 1,903 | 2,351 |
| Average length of stay | 9.1 days | 5.6 days | 8.9 days | 8.9 days |
| Average daily census | 10.0 | 0.7 | 46.5 | 57.1 |
5,490
Medicare Advantage days
594 discharges
3,845
Medicaid managed care days
397 discharges
944
Observation bed days
| Unit | Beds | Inpatient days | Medicare days | Occupancy |
|---|---|---|---|---|
| Adults & pediatrics | 104 | 18,304 | 3,058 | 55% |
| Intensive care unit | 11 | 2,549 | 583 | 64% |
Source: CMS cost report (HCRIS, Form 2552-10), report 831495, as submitted. Hospitals report these figures themselves; they are not audited financial statements. Worksheet S-3 Part I.
What Karmanos Cancer Institute treats Medicare patients for most often, in 2024. 110 Medicare discharges in 6 published DRGs; 10% surgical; 71% in DRGs with complications (CC or MCC).
| Condition or procedure | Discharges | Average charges | Average Medicare payment | Estimated cost | DRG weight |
|---|---|---|---|---|---|
| Septicemia or severe sepsis without MV >96 hours with MCCMS-DRG 871, medical | 31 | $67,051 | $18,153 | $24,071 | 1.98 |
| Autologous bone marrow transplant with cc/mccMS-DRG 016, medical | 23 | $121,711 | $49,472 | $43,694 | 6.18 |
| Allogeneic bone marrow transplantMS-DRG 014, medical | 17 | $526,137 | $156,007 | $188,883 | 11.46 |
| Chemotherapy with acute leukemia as secondary diagnosis or with high dose chemotherapy aMS-DRG 837, medical | 15 | $87,865 | $40,094 | $31,544 | 4.84 |
| Chemotherapy without acute leukemia as secondary diagnosis with CCMS-DRG 847, medical | 13 | $34,631 | $10,225 | $12,433 | 1.21 |
| Major chest procedures with CCMS-DRG 164, surgical | 11 | $53,013 | $20,079 | $19,032 | 2.55 |
Source: CMS Medicare Inpatient Hospitals by Provider and Service (2024 data, released 2026-04-10), traditional Medicare only; CMS omits DRGs with fewer than 11 discharges. Estimated cost is average charges times the hospital's Medicare cost-to-charge ratio from the IPPS Impact File. Weights are the MS-DRG relative weights for the same year.
The comprehensive outpatient service groups (APCs) Karmanos Cancer Institute billed Medicare for most in 2024: 982 services in all.
| Service group | Services | Patients | Average charges | Average Medicare payment | US average payment |
|---|---|---|---|---|---|
| Level 2 Excision/ Biopsy/ Incision and DrainageAPC 5072 | 219 | 205 | $6,019 | $1,123 | $1,220 |
| Level 2 Urology and Related ServicesAPC 5372 | 154 | 56 | $3,270 | $469 | $502 |
| Level 3 Excision/ Biopsy/ Incision and DrainageAPC 5073 | 109 | 85 | $10,631 | $1,957 | $2,141 |
| Level 3 Vascular ProceduresAPC 5183 | 106 | 99 | $14,514 | $2,237 | $2,405 |
| Level 2 Vascular ProceduresAPC 5182 | 53 | 47 | $11,255 | $1,083 | $1,204 |
| Comprehensive Observation ServicesAPC 8011 | 51 | 37 | $12,638 | $1,921 | $2,090 |
| Level 3 Urology and Related ServicesAPC 5373 | 32 | 26 | $7,275 | $1,429 | $1,516 |
| Level 4 Urology and Related ServicesAPC 5374 | 32 | 25 | $12,979 | $2,446 | $2,629 |
| Level 5 ENT ProceduresAPC 5165 | 27 | 26 | $16,942 | $4,109 | $4,436 |
| Level 2 Laparoscopy and Related ServicesAPC 5362 | 26 | 26 | $24,896 | $7,430 | $8,164 |
See all 20 Medicare outpatient services at Karmanos Cancer Institute
Source: CMS Medicare Outpatient Hospitals by Provider and Service (2024 data, released 2026-06-24), comprehensive APCs for traditional Medicare; CMS omits services with fewer than 11 claims. The US average weights every hospital by its services.
ZIP codes with the most Medicare inpatient stays at Karmanos Cancer Institute in 2025. Market share is this hospital's part of every hospital's Medicare stays from the ZIP code. Its published Medicare stays went from 499 in 2020 to 451 in 2025.
| ZIP code | Stays | Of this hospital's stays | Days | Charges | Market share | Share in 2020 |
|---|---|---|---|---|---|---|
| 48207 | 33 | 7% | 314 | $2.5M | 2% | 3% |
| 48238 | 27 | 6% | 205 | $2M | 2% | 1% |
| 48235 | 25 | 6% | 226 | $1.7M | 1% | 1% |
| 48214 | 24 | 5% | 261 | $1.7M | 2% | 2% |
| 48213 | 23 | 5% | 130 | $718,463 | 1% | 1% |
| 48146 | 18 | 4% | 148 | $2.8M | 1% | 1% |
| 48180 | 17 | 4% | 153 | $1.7M | 0% | 0% |
| 48234 | 17 | 4% | 153 | $1.4M | 1% | 1% |
| 48042 | 16 | 4% | 157 | $3.1M | 1% | |
| 48066 | 16 | 4% | 175 | $1.7M | 1% | |
| 48201 | 16 | 4% | 92 | $638,518 | 1% | 3% |
| 48204 | 16 | 4% | 126 | $1M | 1% | |
| 48312 | 16 | 4% | 115 | $2.5M | 1% | |
| 48219 | 15 | 3% | 104 | $1M | 0% | 1% |
| 48021 | 14 | 3% | 94 | $731,087 | 1% | |
| 48060 | 14 | 3% | 175 | $1.6M | 0% | |
| 48075 | 13 | 3% | 70 | $450,042 | 1% | |
| 48081 | 13 | 3% | 88 | $1.2M | 1% | |
| 48126 | 13 | 3% | 152 | $1.1M | 1% | 1% |
| 48223 | 13 | 3% | 79 | $863,487 | 1% | |
| 48101 | 12 | 3% | 65 | $687,383 | 1% | |
| 48183 | 12 | 3% | 104 | $813,466 | 0% | |
| 48205 | 12 | 3% | 95 | $677,198 | 1% | 1% |
| 48212 | 12 | 3% | 54 | $520,864 | 1% | 2% |
| 48135 | 11 | 2% | 158 | $1.6M | 1% |
Source: CMS Hospital Service Area file. Shares are of the 451 stays from ZIP codes CMS publishes; it omits ZIP codes with fewer than 11 stays, so market shares count published stays only.
Staff by profession and the rooms and units Karmanos Cancer Institute reported at its latest Medicare certification survey (2005). Counts are people, not full-time equivalents.
102
Registered nurses
15
Licensed practical nurses
11
Physicians
16
Nurse practitioners
12
Physician assistants
10
Pharmacists
48
Radiology technicians
2
Dietitians
9
Social workers
307
Other personnel
Source: CMS Provider of Services file.
331 clinicians who bill Medicare list Karmanos Cancer Institute as a hospital affiliation. Showing 24 of them. Book a demo to see the commercial rates insurers publish for them, or start a free trial.
Tamam Mohamad
Interventional Cardiology Physician
NPI 1457687584
See commercial rates for Tamam MohamadAriel Majjhoo
Interventional Pain Medicine Physician
NPI 1780874909
See commercial rates for Ariel MajjhooM. Chadi Alraies, MD
Interventional Cardiology Physician
NPI 1689828238
See commercial rates for M. Chadi Alraies, MDYahya Murad, MD
Geriatric Medicine (Internal Medicine) Physician
NPI 1578644712
See commercial rates for Yahya Murad, MDAshish Mody, M.D.
Diagnostic Radiology Physician
NPI 1235183831
See commercial rates for Ashish Mody, M.D.Rafic Beydoun, MD
Anatomic Pathology & Clinical Pathology Physician
NPI 1831455138
See commercial rates for Rafic Beydoun, MDArif Hakim, M.D.
Cardiovascular Disease Physician
NPI 1831267376
See commercial rates for Arif Hakim, M.D.Hammam Zmily, MD
Cardiovascular Disease Physician
NPI 1275736886
See commercial rates for Hammam Zmily, MDOscar Signori, MD
Hematology & Oncology Physician
NPI 1285601435
See commercial rates for Oscar Signori, MDRichard Amato, M.D.
Diagnostic Radiology Physician
NPI 1366423840
See commercial rates for Richard Amato, M.D.Michael Aulicino, MD
Anatomic Pathology & Clinical Pathology Physician
NPI 1689614554
See commercial rates for Michael Aulicino, MDZaher Hakim, M.D
Interventional Cardiology Physician
NPI 1306191853
See commercial rates for Zaher Hakim, M.DMarilynn Fairfax, MD
Clinical Pathology Physician
NPI 1962440081
See commercial rates for Marilynn Fairfax, MDJames Glazier, MD
Cardiovascular Disease Physician
NPI 1346280260
See commercial rates for James Glazier, MDRichard Krikorian, DO
Diagnostic Radiology Physician
NPI 1700807104
See commercial rates for Richard Krikorian, DOVictoria Swegles, DO
Diagnostic Radiology Physician
NPI 1942395827
See commercial rates for Victoria Swegles, DOBerhane Seyoum, MD, MPH
Endocrinology, Diabetes & Metabolism Physician
NPI 1699702241
See commercial rates for Berhane Seyoum, MD, MPHFaisal Qureshi, MD
Anatomic Pathology & Clinical Pathology Physician
NPI 1134167208
See commercial rates for Faisal Qureshi, MDKamalakar Nerusu, MD
Internal Medicine Physician
NPI 1609042183
See commercial rates for Kamalakar Nerusu, MDJames Denier, M.D.
Diagnostic Radiology Physician
NPI 1780689497
See commercial rates for James Denier, M.D.Luis Afonso, MD
Cardiovascular Disease Physician
NPI 1023058575
See commercial rates for Luis Afonso, MDTimothy Kennedy, M.D.
Anatomic Pathology & Clinical Pathology Physician
NPI 1356311955
See commercial rates for Timothy Kennedy, M.D.Kimberly Hart, MD
Radiation Oncology Physician
NPI 1033159900
See commercial rates for Kimberly Hart, MDYogesh Mody, MD
Diagnostic Radiology Physician
NPI 1255354791
See commercial rates for Yogesh Mody, MDSource: CMS Doctors and Clinicians facility affiliations, released 2026-10-15, with names and specialties from NPPES. Affiliation means the clinician bills Medicare for care at this hospital; it is not employment.
Revenue, expenses and income Karmanos Cancer Institute reported to Medicare for Oct 1, 2024 to Sep 30, 2025. Percentages are of net patient revenue.
| Line | Amount | Share |
|---|---|---|
| Gross patient revenue (charges) | $1.6B | 402.7% |
| Inpatient | $257.3M | 64.1% |
| Outpatient | $1.4B | 338.6% |
| Contractual allowances and discounts | -$1.2B | -302.7% |
| Net patient revenue | $401.6M | 100.0% |
| Operating expenses | -$523.1M | -130.3% |
| Operating income from patient care | -$121.5M | -30.3% |
| Other income | $176.8M | 44.0% |
| Contributions and donations | $22,568 | 0.0% |
| Investment income | $2.6M | 0.6% |
| Other | $174.2M | 43.4% |
| Net income | $55.3M | 13.8% |
| Line | Amount | Share |
|---|---|---|
| Traditional Medicare | $281.5M | 17.9% |
| Medicaid (including managed care) | $244.2M | 15.5% |
| Other payers and self-pay | $1B | 66.6% |
| Total charges | $1.6B | 100.0% |
Source: CMS cost report (HCRIS, Form 2552-10), report 831495, as submitted. Hospitals report these figures themselves; they are not audited financial statements. Traditional Medicare is the program charges on Worksheets D-3 and D Part V; Medicaid is from Worksheet S-10.
Computed from Karmanos Cancer Institute's latest cost report.
-30.3%
Operating margin
Operating income from patient care / net patient revenue
9.6%
Total margin
Net income / net patient revenue plus other income
11.6%
EBITDAR margin
Net income before interest, depreciation and leases (Worksheet A-7), / total revenue
23% of expenses
Personnel costs
Salaries, direct-care contract labor and core wage-related costs / operating expenses
$50.42
Average hourly wage
Adjusted salaries / paid hours (Worksheet S-3 Part II)
23.1%
Return on assets
Net income for a year / total assets
65.6%
Return on equity
Net income for a year / fund balance
0.44
Long-term debt to fund balance
Mortgages, notes and loans / fund balance
1.18
Current ratio
Current assets / current liabilities
0.51
Quick ratio
Cash, temporary investments and net receivables / current liabilities
3 days
Days cash on hand
Cash and temporary investments / daily operating expenses excluding depreciation
48 days
Days in patient receivables
Net patient receivables / daily net patient revenue
81 days
Average payment period
Current liabilities / daily operating expenses excluding depreciation
2.42
Asset turnover
Total revenue for a year / total assets
6.1 years
Average age of plant
Accumulated depreciation / depreciation for a year
Source: CMS cost report (HCRIS, Form 2552-10), report 831495, as submitted. Hospitals report these figures themselves; they are not audited financial statements.
What Karmanos Cancer Institute owned and owed at the end of its reporting period (Sep 2025), across all fund types: $239.4M in total assets and a $84.4M fund balance.
| Line | Amount | Of total assets |
|---|---|---|
| Cash and temporary investments | $4.2M | 1.7% |
| Patient receivables, net | $53.3M | 22.3% |
| Inventory | $15.8M | 6.6% |
| Total current assets | $133.7M | 55.8% |
| Property and equipment, net of depreciation | $86M | 35.9% |
| Investments and other assets | $19.8M | 8.3% |
| Total assets | $239.4M | 100.0% |
| Current liabilities | $113M | 47.2% |
| Long-term debt | $37.5M | 15.7% |
| Total liabilities | $155M | 64.8% |
| Fund balance (net assets) | $84.4M | 35.2% |
Source: CMS cost report (HCRIS, Form 2552-10), report 831495, as submitted. Hospitals report these figures themselves; they are not audited financial statements.
Care Karmanos Cancer Institute provided without full payment, as reported on Worksheet S-10 of its cost report.
$518,085
Cost of charity care
Care for patients approved for charity care and uninsured discounts, at cost
$7.2M
Bad debt
Patient bills written off as uncollectible, at charges
$20.8M
Medicaid shortfall
Cost of Medicaid patients (charges times the cost-to-charge ratio) minus Medicaid payments; negative means a surplus
$2.2M
Total unreimbursed and uncompensated care
0.4% of operating expenses
Medicaid, CHIP and indigent care shortfalls plus charity care and the cost of bad debt (Worksheet S-10 line 31)
Source: CMS cost report (HCRIS, Form 2552-10), report 831495, as submitted. Hospitals report these figures themselves; they are not audited financial statements.
Karmanos Cancer Institute's full-year cost reports, by fiscal year end. Reports shorter than ten months are left out.
| Fiscal year ending | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|
| Net patient revenue | $222.2M | $271.9M | $284.8M | $335.6M | $396.5M | $401.6M |
| Operating expenses | $290.3M | $337M | $363.8M | $419.2M | $480.4M | $523.1M |
| Operating margin | -30.6% | -23.9% | -27.8% | -24.9% | -21.2% | -30.3% |
| Net income | $20.5M | $20.4M | $24.3M | $39.7M | $64.6M | $55.3M |
| Total assets | $258.9M | $289.8M | $288.6M | $103.8M | $213.6M | $239.4M |
| Discharges | 2,660 | 2,694 | 2,183 | 2,176 | 2,240 | 2,351 |
| Inpatient days | 22,908 | 23,612 | 20,973 | 20,681 | 20,130 | 20,853 |
| Medicare Advantage days | 4,800 | 5,316 | 6,173 | 4,829 | 4,841 | 5,490 |
| Beds | 123 | 123 | 106 | 102 | 111 | 115 |
| Employees (FTE) | 719 | 725 | 682 | 771 | 810 | 976 |
Source: CMS cost report (HCRIS, Form 2552-10), report 831495, as submitted. Hospitals report these figures themselves; they are not audited financial statements.
Each cost center Karmanos Cancer Institute reports, largest first. Total cost includes its share of overhead; the cost-to-charge ratio is total cost / charges.
| Department | Salaries | Total cost | Charges | Cost-to-charge | Square feet |
|---|---|---|---|---|---|
| Drugs charged to patients | $10.1M | $116M | $976.2M | 0.12 | 16,270 |
| Clinic | $22.8M | $32.3M | $22M | 1.47 | 133,796 |
| Car t-cell immunotherapy | $24.2M | $62.9M | 0.39 | ||
| Laboratory | $21.4M | $87.3M | 0.25 | 5,281 | |
| Radiology-therapeutic | $5.3M | $18.4M | $146.6M | 0.13 | |
| Radiology-diagnostic | $10.5M | $15.9M | $32.9M | 0.48 | 46,032 |
| Operating room | $1.1M | $15M | $27M | 0.56 | |
| Ct scan | $1.9M | $9.6M | $67.2M | 0.14 | 12,442 |
| Intravenous therapy | $5.4M | $8.5M | $23.9M | 0.36 | |
| Allogeneic hsct acquisition | $3.7M | $5.1M | 0.73 | ||
| Recovery room | $3.6M | $4M | 0.89 | ||
| Respiratory therapy | $2.5M | $3.5M | 0.72 | ||
| Mri | $288,380 | $2.4M | $27.4M | 0.09 | |
| Impl. dev. charged to patients | $1.6M | $10.2M | 0.16 | ||
| Radioisotope | $1.6M | $1.9M | 0.84 | ||
| Whole blood & packed red blood cell | $968,281 | $1.5M | $3.8M | 0.38 | |
| Medical supplies charged to patient | $1.4M | $5.9M | 0.24 | ||
| Observation beds (non-distinct part | $1.3M | $3.5M | 0.36 | ||
| Anesthesiology | $1.2M | $5.4M | 0.22 | ||
| Blood storing processing & trans. | $481,701 | $723,430 | $1.5M | 0.50 | |
| Physical therapy | $683,992 | $1M | 0.68 | ||
| Cardiac catheterization | $394,898 | $1.2M | 0.34 | ||
| Occupational therapy | $258,544 | $761,636 | 0.34 | ||
| Endoscopy | $248,652 | $1.1M | 0.23 | ||
| Electrocardiology | $245,982 | $318,360 | 0.77 | ||
| Electroencephalography | $193,988 | $650,459 | 0.30 | ||
| Speech pathology | $145 | $4,633 | 0.03 |
| Department | Salaries | Total cost | Charges | Cost-to-charge | Square feet |
|---|---|---|---|---|---|
| Adults & pediatrics | $13M | $25.6M | $37.7M | 0.68 | 38,518 |
| Intensive care unit | $3.6M | $7.2M | $12.9M | 0.56 | 12,720 |
| Department | Salaries | Direct cost | Paid hours | Average hourly wage | Square feet |
|---|---|---|---|---|---|
| Administrative & general | $12.1M | $41.2M | 323,940 | $37.31 | 143,932 |
| Operation of plant | $1.6M | $18.4M | 50,727 | $31.31 | |
| Employee benefits department | $12.1M | ||||
| Cap rel costs-mvble equip | $8.4M | ||||
| Cap rel costs-bldg & fixt | $3.7M | 424,842 | |||
| Nursing administration | $2.3M | $2.6M | 38,317 | $59.24 | |
| I&r services-salary & fringes apprv | $2.2M | 1,489 | |||
| Social service | $1.8M | $1.9M | 42,463 | $42.40 | 1,407 |
| Dietary | $1.6M | ||||
| I&r services-other prgm costs apprv | $1.3M | ||||
| Medical records & library | $898,333 | 12,955 | |||
| Laundry & linen service | $376,733 | ||||
| Housekeeping | $33,575 | ||||
| Pharmacy | -$757,576 |
Source: CMS cost report (HCRIS, Form 2552-10), report 831495, as submitted. Hospitals report these figures themselves; they are not audited financial statements. Worksheets A, B-1, C Part I and S-3 Part II.
The factors Medicare uses to set what it pays Karmanos Cancer Institute for an inpatient stay.
3.20
Case mix index
Higher than 98% of hospitals paid under Medicare IPPS
Average Medicare DRG weight of its inpatient cases (FY 2027); higher means more complex, costlier care.
Major teaching hospital
Teaching status
0.36 residents per bed
Medicare-funded interns and residents per bed (FY 2027).
26.6%
Low-income patient share
Disproportionate share percentage: Medicaid and SSI patient days CMS uses for safety-net payments (FY 2027).
411
Medicare inpatient stays
Medicare claims CMS based FY 2027 payment rates on.
Urban (metro area)
Location type
Geographic area CMS assigns before any wage index reclassification (FY 2027).
| IPPS fiscal year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | FY 2027 |
|---|---|---|---|---|---|---|---|
| Case mix index | 2.30 | 2.26 | 2.60 | 2.77 | 4.03 | 3.65 | 3.20 |
| Wage index | 0.914 | 0.923 | 0.911 | 0.899 | 0.967 | 0.960 | 0.956 |
| Readmissions adjustment | 0.00% | 0.00% | -0.03% | 0.00% | -0.01% | 0.00% | 0.00% |
| Value-based purchasing adjustment | -0.37% | +0.22% | +0.22% | +0.06% | +1.05% | +0.98% | 0.00% |
| Medicare inpatient stays | 833 | 833 | 565 | 485 | 472 | 472 | 411 |
Source: CMS IPPS final rule Impact File (FY 2027).
Organizations Karmanos Cancer Institute reports to Medicare as owners or with operational control. 2 individuals also hold ownership interests; they are not listed here.
Barbara Ann Karmanos Cancer Institute
5% or greater direct ownership interest, 100%, since 2004
McLaren Health Care Corporation
Operational/managerial control, since 2014
Sources: CMS Hospital All Owners.
The officers and board members on Karmanos Cancer Institute's Medicare enrollment and on the IRS Form 990 filed under its tax ID.
Source: CMS Hospital All Owners (PECOS), the people the hospital lists on its Medicare enrollment; the first 19 of 23 are shown.
Barbara Ann Karmanos Cancer Hospital files the Form 990 for the tax ID insurers list for Karmanos Cancer Institute, so these people may lead the wider organization rather than Karmanos Cancer Institute alone.
| Name | Title |
|---|---|
| Brian Gamble | President Kcc |
| Boris Pasche MD | Board Member/president Kci |
| Regina Doxtader | VP CFO & Secretary |
| Christopher D Graunstadt | VP, Operations |
| Kathleen Carolin | VP, Chief Nursing Officer - Part Year |
| Jacob Burmeister | Chief Of Physics |
| Kathleen Fedoronko | VP, Chief Nursing Officer |
| Stephen Smith | VP Chief Pharmacy Officer |
| Jose Saldivar | Dir Facilities Maintenance |
| George H Yoo MD | Board Member/chief Medical Officer |
| Surender Kanaparthi | VP Chief Pharmacy Officer |
| Scott Hunter | Board Member/chair |
Board members: Philip Incarnati, Timonthy Monahan, Daniel Ret, David E Duprey, Deborah Savoie, Debra Patrich, Geaneen M Arends, Hussein Aoun, Kelley Lafontaine, Kimberly Espy, Michael Duhaime, Shari Ferber-Kaufman, Sylvester Hester, Tom Kalas, Wael Sakr.
Source: IRS Form 990 Part VII filed by Barbara Ann Karmanos Cancer Hospital (EIN 20-1649466), via the IRS e-file data. A health system's return can cover several hospitals.
340B drug pricing program
Participating since 2006
340B ID DSH230297, registered as a disproportionate share hospital; 16 registered outpatient sites; 6 active contract pharmacies. Authorizing official: Regina Doxtader, Vp-chief Financial Officer.
Source: HRSA 340B Office of Pharmacy Affairs Information System.
Accountable care organization (Medicare Shared Savings Program)
McLaren High Performance Network, LLC
ACO A3317, current agreement since 2025. Public reporting page
Source: CMS Shared Savings Program participants, 2026, matched on Karmanos Cancer Institute's legal name.
Helipad
Detroit Medical Center
FAA location ID 5MI0, a medical-use heliport 0.2 mi from the hospital.
Source: FAA National Airspace System Resource data, cycle 2026-10-01.
About Karmanos Cancer Institute's rates and hospital price transparency.
For MRI brain before and after contrast (CPT 70553), published negotiated rates at Karmanos Cancer Institute range from $277 to $5,431 across 3 insurers. Aetna's rate is $5,431. The median at nearby comparable hospitals is $1,951. What a patient pays depends on their plan's deductible, coinsurance and network status.
For CT abdomen and pelvis with contrast (CPT 74177), published negotiated rates at Karmanos Cancer Institute range from $277 to $2,049 across 3 insurers. UnitedHealthcare's rate is $277. The median at nearby comparable hospitals is $1,553. What a patient pays depends on their plan's deductible, coinsurance and network status.
For Colonoscopy with polyp removal (CPT 45385), published negotiated rates at Karmanos Cancer Institute range from $1,034 to $3,319 across 3 insurers. Blue Cross Blue Shield's rate is $1,034. The median at nearby comparable hospitals is $5,218. What a patient pays depends on their plan's deductible, coinsurance and network status.
For Screening mammography, bilateral (CPT 77067), published negotiated rates at Karmanos Cancer Institute range from $88 to $424 across 3 insurers. Aetna's rate is $424. The median at nearby comparable hospitals is $318. What a patient pays depends on their plan's deductible, coinsurance and network status.
Karmanos Cancer Institute has a CMS overall hospital star rating of 3 out of 5 on Medicare Care Compare (CMS data released 2026-08-13). That is lower than 42% of US hospitals.
Yes. CMS counts 0.36 Medicare-funded residents per bed at Karmanos Cancer Institute for fiscal year 2027, so it is a major teaching hospital.
No. Karmanos Cancer Institute has no Hospital Readmissions Reduction Program penalty in fiscal year 2027.
In 2024, the most common were septicemia or severe sepsis without mv >96 hours with mcc (31 discharges), autologous bone marrow transplant with cc/mcc (23 discharges), allogeneic bone marrow transplant (17 discharges).
Karmanos Cancer Institute's Medicare case mix index is 3.20 for fiscal year 2027, higher than 98% of hospitals paid under the inpatient prospective payment system.
Karmanos Cancer Institute reported 2,351 inpatient discharges and 20,853 inpatient days from Oct 1, 2024 to Sep 30, 2025.
Karmanos Cancer Institute reported 976 full-time-equivalent employees on payroll from Oct 1, 2024 to Sep 30, 2025.
Karmanos Cancer Institute reported $401.6M in net patient revenue on $1.6B of gross charges for Oct 1, 2024 to Sep 30, 2025, an operating margin of -30.3%, and net income of $55.3M.
Karmanos Cancer Institute reported $2.2M of unreimbursed and uncompensated care for Oct 1, 2024 to Sep 30, 2025, including $518,085 of charity care at cost.
Karmanos Cancer Institute's Medicare enrollment lists Brian R Gamble as Ceo/president since 2015.
Insurers' price transparency files list Karmanos Cancer Institute under employer identification number 20-1649466 (Barbara Ann Karmanos Cancer Hospital). 46 health plans and networks list 20-1649466 for it.
Yes. HRSA's 340B database lists Karmanos Cancer Institute (340B ID DSH230297) as a participating disproportionate share hospital since 2006, with 6 active contract pharmacies.
331 clinicians who bill Medicare list Karmanos Cancer Institute as a hospital affiliation in CMS's Doctors and Clinicians data. The largest groups are certified registered nurse anesthetist (33), internal medicine physician (29), anesthesiology physician (24).
Yes. CMS's Provider of Services file lists The Joint Commission as the accrediting organization for Karmanos Cancer Institute, effective 2020.
In its Medicare enrollment, Karmanos Cancer Institute reports Barbara Ann Karmanos Cancer Institute as 5% or greater direct ownership interest (100%).
CMS lists 33 services at Karmanos Cancer Institute, including Acute Renal Dialysis, Anesthesia, Cardiac Catheterization Lab, Chemotherapy, Clinical Laboratory, Coronary Care Unit.
In CMS's 2025 Hospital Service Area file, the most Medicare inpatient stays at Karmanos Cancer Institute came from ZIP codes 48207 (33), 48238 (27), 48235 (25).
Karmanos Cancer Institute has 115 beds, including its psychiatric, rehabilitation and other subprovider units, in its latest Medicare cost report. 123 are Medicare-certified beds in CMS's Provider of Services file. Facility type: Short Term Acute Care Hospital.
Karmanos Cancer Institute is located at 4100 John 'r' Street, Detroit, MI 48201. Its main phone number is (800) 576-6266.
Karmanos Cancer Institute's CMS Certification Number (CCN), also called its Medicare provider number, is 230297.
The National Provider Identifier (NPI) on file for Karmanos Cancer Institute is 1316900277.
Karmanos Cancer Institute is affiliated with McLaren Health Care Corporation.
Karmanos Cancer Institute lists 26 in-network payers, including Aetna, Ameri Health, Avera Health Plans, BCBS, and is Medicare-certified. Insurance acceptance may vary by plan, so confirm coverage with your insurer or the hospital's billing department.
299 disclosed rate categories. Each shows the payer, category, code type and group with its code range, and contract type, along with how the rate compares with the state average.
Under 45 CFR Part 180, every US hospital must publish a machine-readable file of its standard charges, including gross charges, discounted cash prices and payer-specific negotiated rates, in the CMS template format. PayerPrice can help hospitals publish and maintain these files.
A chargemaster (charge description master, or CDM) is a hospital's master list of billable items, with codes, descriptions and gross charges. A chargemaster review looks at those lines for accuracy and pricing. PayerPrice can help hospitals review their chargemaster; contact us to discuss your needs.
For hospital finance and compliance teams
The data on this page comes from the files hospitals and payers publish. We help hospitals publish theirs correctly, and take a fresh look at their chargemaster.
We turn your chargemaster and payer contracts into the CMS template file, then keep it current as rates change.
{
"description": "MRI of brain (no contrast)",
"code_information": [
{ "code": "611", "type": "RC" },
{ "code": "70551", "type": "CPT" }
],
"standard_charges": [{
"setting": "outpatient",
"minimum": 250,
"maximum": 400,
"gross_charge": 1200,
"discounted_cash": 1080,
"payers_information": [
{
"payer_name": "Platform Health Insurance",
"plan_name": "PPO",
"methodology": "fee schedule",
"standard_charge_dollar": 400
},
{
"payer_name": "Region Health Insurance",
"plan_name": "HMO",
"methodology": "fee schedule",
"standard_charge_dollar": 250
}
]
}]
}Your chargemaster sets the gross charge on every claim, and many payer contracts base payment on it through percent-of-charge, lesser-of and stop-loss terms. We audit it line by line and show how your charges and negotiated rates compare with peer hospitals before your next negotiation.
What a review covers